PT - JOURNAL ARTICLE AU - Zhou, Yekai AU - Lin, Jiaxi AU - Yu, Qiuyan AU - Blais, Joseph Edgar AU - Wan, Eric Yuk Fai AU - Lee, Marco AU - Wong, Emmanuel AU - Siu, David Chung-Wah AU - Wong, Vincent AU - Chan, Esther Wai Yin AU - Lam, Tak-Wah AU - Chui, William AU - Wong, Ian Chi Kei AU - Luo, Ruibang AU - Chui, Celine SL TI - Development and validation of risk prediction model for recurrent cardiovascular events among Chinese: P-CARDIAC model AID - 10.1101/2023.10.17.23297127 DP - 2023 Jan 01 TA - medRxiv PG - 2023.10.17.23297127 4099 - http://medrxiv.org/content/early/2023/10/17/2023.10.17.23297127.short 4100 - http://medrxiv.org/content/early/2023/10/17/2023.10.17.23297127.full AB - This study aimed to develop and validate a cardiovascular diseases (CVD) risk prediction model, Personalized CARdiovascular DIsease risk Assessment for Chinese (P-CARDIAC), for recurrent cardiovascular events using Machine-Learning technique.Three cohorts of Chinese patients with established CVD in Hong Kong were included; Hong Kong Island cohort as the derivation cohort, whilst the Kowloon and New Territories cohorts were validation cohorts. The 10-year CVD outcome was a composite of diagnostic or procedure codes for coronary heart disease, ischaemic or haemorrhagic stroke, peripheral artery disease, and revascularization. We estimated incidence of recurrent CVD events for each cohort with reference to the total person-years of each cohort. Multivariate imputation with chained equations (MICE) and XGBoost were applied for the model development. The comparison with TRS-2°P and SMART2 used the validation cohorts with 1000 bootstrap replicates.A total 48,799, 119,672 and 140,533 patients were included in the derivation and validation cohorts, respectively. A list of 125 risk variables were used to make predictions on CVD risk, of which, eight classes of medications were considered interactive drug use. Model performance in the derivation cohort showed satisfying discrimination and calibration with a C-statistic of 0·69. Internal validation showed good discrimination and calibration performance with C-statistic over 0·6. P-CARDIAC also showed better performance than TRS-2°P and SMART2.Compared to other risk scores, P-CARDIAC enables to identify unique patterns of Chinese patients with established CVD. We anticipate that P-CARDIAC can be applied in various settings to prevent recurrent CVD events, thus reducing the related healthcare burden.Condensed Abstract A CVD risk prediction model named Personalized CARdiovascular DIsease risk Assessment for Chinese (P-CARDIAC), for recurrent cardiovascular events among Chinese adults using Machine-Learning technique was newly developed. It predicted 10-year CVD outcome including a composite of diagnostic or procedure codes for coronary heart disease, ischaemic or haemorrhagic stroke, peripheral artery disease, and revascularization by incidence of recurrent CVD. Model showed satisfying discrimination and calibration with a C-statistic of 0·69. P-CARDIAC also showed better performance than existing risk scores, such as TRS-2°P and SMART2. P-CARDIAC could help predict recurrent CVD risk and reduce the healthcare burden.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project is funded by Hong Kong Innovation and Technology Bureau (ref no: PRP/070/19FX) and Amgen Hong Kong Limited.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this study was granted by the Institutional Review Board of the University of Hong Kong/HA Hong Kong West Cluster (UW20-073).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsCVDCardiovascular DiseaseP-CARDIACPersonalized CARdiovascular DIsease risk Assessment for ChineseTRS-2°PThrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary PreventionSMART2Secondary Manifestations of ARTerial diseaseMLMachine-LearningEHRElectronic Health RecordsHAHospital AuthorityICD-9-CMNinth Revision, Clinical ModificationBNFBritish National FormularyMICEMultivariate imputation with chained equationsCPHCox proportional hazards modelLASSOLeast Absolute Shrinkage and Selection OperatorCHDCoronary Heart DiseasePADPeripheral Arterial DiseaseMIMyocardial Infarction